Easy and efficient protocols for working with recombinant vaccinia virus MVA.
Easy and efficient protocols for working with recombinant vaccinia virus MVA.
复制标题
DOI：
10.1007/978-1-61779-876-4_4
复制
发表时间：
2012-01-01
期刊：
影响因子：
--
通讯作者：
Sutter, Gerd
中科院分区：
文献类型：
--
作者：
Kremer, Melanie;Volz, Asisa;Sutter, Gerd
改良的安卡拉牛痘病毒（MVA）是高度减毒和复制缺陷型的牛痘病毒株，其越来越多地用作研究实验室和生物医学中用于疫苗开发的重组基因表达的载体。MVA的主要优点包括与常规牛痘病毒相比具有明显的安全优势，在病毒基因工程方面的长期经验，以及在工业规模上建立病毒生产程序的可用性。MVA载体可以在生物安全1级条件下处理，并且已经证明当在动物和人类中递送各种异源抗原时，多种重组MVA疫苗具有免疫原性和保护性。在这一章中，我们提供了方便的国家的最先进的协议，重组MVA病毒的生成，扩增和纯化。重要的是，我们包括严格的质量控制方法，以获得最佳的载体病毒，用于进一步的研究，包括临床评价。
Modified vaccinia virus Ankara (MVA) is a highly attenuated and replication-deficient strain of vaccinia virus that is increasingly used as vector for expression of recombinant genes in the research laboratory and in biomedicine for vaccine development. Major benefits of MVA include the clear safety advantage compared to conventional vaccinia viruses, the longstanding experience in the genetic engineering of the virus, and the availability of established procedures for virus production at an industrial scale. MVA vectors can be handled under biosafety level 1 conditions, and a multitude of recombinant MVA vaccines has proven to be immunogenic and protective when delivering various heterologous antigens in animals and humans. In this chapter we provide convenient state-of-the-art protocols for generation, amplification, and purification of recombinant MVA viruses. Importantly, we include methodology for rigid quality control to obtain best possible vector viruses for further investigations including clinical evaluation.